This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soto, M. Articles by Alonso, C. Search for Related Content PubMed PubMed Citation Articles by Soto, M. Articles by Alonso, C.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 07 1996, 387-391, Vol 3, No. 4
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins

M Soto, JM Requena, L Quijada and C Alonso
Centro de Biologia Molecular Severo Ochoa (Consejo Superior de Investigaciones Cientificas-Universidad Autonoma de Madrid), Universidad Autonoma de Madrid, Spain.

The Leishmania P2 proteins have been analyzed as potential tools for the immunodiagnosis of human mucocutaneous and visceral leishmaniasis. Two recombinant Leishmania infantum proteins, rLIP2a and rLip2b, were used. The analysis indicated that the rLiP2a and rLiP2b proteins are recognized by 76% (16 of 21) and 42% (9 of 21), respectively, of sera from patients with mucocutaneous leishmaniasis and by 50% (5 of 10) and 40% (4 of 10), respectively, of sera from patients with visceral leishmaniasis. The Leishmania P2 proteins were engineered to have deletions of particular amino acids from the carboxyl-terminal region in order to avoid cross-reactivity with sera from patients with systemic lupus erythematosus and Chagas' disease, since it is known that this region is the main target of the autoantibodies present in sera from these patients. The results show that while the modified recombinant proteins rLiP2a-Q and rLiP2b-Q, in which the five carboxyl- terminal amino acids had been deleted, maintain the leishmaniasis- specific epitopes, they do not react with sera from patients with autoimmune disease and Chagas' disease. For this reason, and also because the sera from patients with tuberculosis and leprosy, diseases that have to be considered in a differential clinical diagnosis of infectious diseases, do not react with the rLiP2a-Q or rLiP2b-Q protein, we think that the engineered proteins may be considered specific tools for the immunodiagnosis of mucocutaneous and visceral leishmaniasis.

This article has been cited by other articles:

• DE SOUZA DIAS, S., DA COSTA PINHEIRO, P. H., KATZ, S., SANTOS, M. R. M. D., BARBIERI, C. L. (2005). A RECOMBINANT CYSTEINE PROTEINASE FROM LEISHMANIA (LEISHMANIA) CHAGASI SUITABLE FOR SERODIAGNOSIS OF AMERICAN VISCERAL LEISHMANIASIS. Am J Trop Med Hyg 72: 126-132 [Abstract] [Full Text]  
• Soto, M, Requena, J., Quijada, L, Alonso, C (1998). Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis [In Process Citation]. J. Clin. Microbiol. 36: 58-63 [Abstract] [Full Text]